Categories: DrugLegalTechProduct
We develop and commercialize innovative oncology products for women’s and pediatric cancers. Our oncology solutions deliver life-saving treatments to patients across the world
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.06.2020 | Series A | $8.3M | - |
Mentions in press and media 6
| Date | Title | Description |
| 10.11.2020 | Shorla Pharma Announces New Board Members, John Moloney and Tracy Woody | |
| 03.06.2020 | Shorla Pharma Raises $8.3M in Series A Funding Round | Shorla Pharma, an Irish specialty pharmaceutical company, completed an $8.3m Series A financing.
The round was led by Seroba Life Sciences with participation from Irish and Canadian based family offices and participation from Enterprise Ire... |
| 03.06.2020 | Ireland's Shorla nabs $8.3M to bring improved cancer meds to the U.S. | When Opko Health bought Ireland’s EirGen in 2015, colleagues Sharon Cunningham and Orlaith Ryan wasted no time. Zeroing in on gaps in cancer care, the duo started building its own oncology company, with a focus on children’s and women’s can... |
| - | Shorla Pharma Closes $8.3m Series A Funding Round | Dublin and Clonmel, Ireland. June 4, 2020. Shorla Pharma Limited (‘Shorla’), an Irish specialty pharmaceutical company has today announced the completion of a Series A investment of $8.3m. The financing was led by Seroba Life Sciences (‘Ser... |
| - | Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-cell Leukemia Treatment | Clonmel, Ireland. April 23, 2021. Seroba’s portfolio company, Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing... |
| - | Shorla Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment. | Cambridge, Massachusetts, USA. 17 August, 2021. Seroba’s portfolio company, Shorla Pharma (‘Shorla’), a specialty pharmaceutical company and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry,... |
Reviews 0
